PEG — Pharma Equity A/S Share Price
Last trade - 00:00- DKK256.76m
- DKK264.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.6 | ||
| Price to Tang. Book | 10.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.45% | ||
| Return on Equity | -57.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 20th, 2002
- Public Since
- June 25th, 2003
- No. of Employees
- 2
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 1,022,950,278
- Address
- Slotsmarken 18, 2. th., HOERSHOLM, 2970
- Web
- https://pharmaequitygroup.com/
- Phone
- +45 36944417
- Auditors
- BDO Statsautoriseret Revisionsaktieselskab
Upcoming Events for PEG
Similar to PEG
Strategic Investments A/S
OMX Nordic Exchange - Copenhagen
FAQ
As of Today at 19:16 UTC, shares in Pharma Equity A/S are trading at DKK0.25. This share price information is delayed by 15 minutes.
Shares in Pharma Equity A/S last closed at DKK0.25 and the price had moved by -37.87% over the past 365 days. In terms of relative price strength the Pharma Equity A/S share price has underperformed the FTSE Global All Cap Index by -43.08% over the past year.
There is no consensus recommendation for this security.
Pharma Equity A/S does not currently pay a dividend.
Pharma Equity A/S does not currently pay a dividend.
Pharma Equity A/S does not currently pay a dividend.
To buy shares in Pharma Equity A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of DKK0.25, shares in Pharma Equity A/S had a market capitalisation of DKK256.76m.
Here are the trading details for Pharma Equity A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: PEG
Based on an overall assessment of its quality, value and momentum Pharma Equity A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharma Equity A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -55.38%.
As of the last closing price of DKK0.25, shares in Pharma Equity A/S were trading -36.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharma Equity A/S PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at DKK0.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pharma Equity A/S' management team is headed by:
- Peter Jensen - CHM
- Claus Abildstroem - DRC
- Jeanette Borg - DRC